(TECH) Bio-Techne - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US09073M1045
Cytokines, Antibodies, Assays, Instruments, Reagents
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.57% |
| Yield on Cost 5y | 0.37% |
| Yield CAGR 5y | -29.29% |
| Payout Consistency | 95.0% |
| Payout Ratio | 16.6% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 38.9% |
| Value at Risk 5%th | 59.3% |
| Relative Tail Risk | -7.39% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.15 |
| Alpha | -29.94 |
| CAGR/Max DD | -0.11 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.423 |
| Beta | 1.187 |
| Beta Downside | 1.040 |
| Drawdowns 3y | |
|---|---|
| Max DD | 47.32% |
| Mean DD | 21.90% |
| Median DD | 19.63% |
Description: TECH Bio-Techne January 06, 2026
Bio-Techne Corp (NASDAQ: TECH) supplies life-science reagents, instruments, and services across research, diagnostics, and bioprocessing, organized into two divisions: Protein Sciences and Diagnostics & Spatial Biology. The Protein Sciences arm produces cytokines, growth factors, antibodies, and automated proteomic tools, while the Diagnostics segment offers assay controls, exosome-based tests, spatial-genomics kits, and hematology reagents.
Key metrics (FY 2023) show revenue of roughly $1.5 billion, up about 10 % YoY, with an operating margin near 13 % and R&D spending at ~12 % of sales-both above the industry average. The company’s growth is bolstered by the ~8 % CAGR expansion of the cell-and-gene-therapy reagent market and rising adoption of spatial-biology platforms, while recent acquisitions (e.g., Asuragen in 2022) have broadened its genomics footprint.
If you want a data-driven, quantitative deep-dive, the analytical tools on ValueRay may be a useful next step.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 78.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -0.09 > 1.0 |
| NWC/Revenue: 38.21% < 20% (prev 43.23%; Δ -5.01% < -1%) |
| CFO/TA 0.10 > 3% & CFO 251.3m > Net Income 78.0m |
| Net Debt (249.5m) to EBITDA (224.2m): 1.11 < 3 |
| Current Ratio: 4.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (156.4m) vs 12m ago -2.95% < -2% |
| Gross Margin: 65.54% > 18% (prev 0.66%; Δ 6488 % > 0.5%) |
| Asset Turnover: 46.24% > 50% (prev 42.82%; Δ 3.42% > 0%) |
| Interest Coverage Ratio: 10.01 > 6 (EBITDA TTM 224.2m / Interest Expense TTM 11.8m) |
Altman Z'' 4.82
| A: 0.18 (Total Current Assets 609.5m - Total Current Liabilities 144.5m) / Total Assets 2.53b |
| B: 0.43 (Retained Earnings 1.08b / Total Assets 2.53b) |
| C: 0.04 (EBIT TTM 118.1m / Avg Total Assets 2.63b) |
| D: 1.82 (Book Value of Equity 1.02b / Total Liabilities 560.3m) |
| Altman-Z'' Score: 4.82 = AA |
Beneish M -3.24
| DSRI: 0.79 (Receivables 183.9m/223.7m, Revenue 1.22b/1.17b) |
| GMI: 1.00 (GM 65.54% / 65.51%) |
| AQI: 1.00 (AQ_t 0.64 / AQ_t-1 0.64) |
| SGI: 1.04 (Revenue 1.22b / 1.17b) |
| TATA: -0.07 (NI 78.0m - CFO 251.3m) / TA 2.53b) |
| Beneish M-Score: -3.24 (Cap -4..+1) = AA |
ValueRay F-Score (Strict, 0-100) 57.33
| 1. Piotroski: 7.50pt |
| 2. FCF Yield: 2.06% |
| 3. FCF Margin: 18.41% |
| 4. Debt/Equity: 0.20 |
| 5. Debt/Ebitda: 1.11 |
| 6. ROIC - WACC: -5.90% |
| 7. RoE: 3.91% |
| 8. Revenue Trend: 59.71% |
| 9. EPS Trend: -46.32% |
What is the price of TECH shares?
As of January 26, 2026, the stock is trading at USD 68.16 with a total of 1,900,426 shares traded.
Over the past week, the price has changed by -2.02%, over one month by +15.10%, over three months by +6.23% and over the past year by -10.34%.
Over the past week, the price has changed by -2.02%, over one month by +15.10%, over three months by +6.23% and over the past year by -10.34%.
Is TECH a buy, sell or hold?
Bio-Techne has received a consensus analysts rating of 4.13.
Therefore, it is recommended to buy TECH.
- Strong Buy: 7
- Buy: 3
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TECH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 70 | 2.7% |
| Analysts Target Price | 70 | 2.7% |
| ValueRay Target Price | 65.7 | -3.6% |
TECH Fundamental Data Overview January 26, 2026
P/E Trailing = 139.1021
P/E Forward = 34.2466
P/S = 8.7285
P/B = 5.4024
P/EG = 0.8316
Revenue TTM = 1.22b USD
EBIT TTM = 118.1m USD
EBITDA TTM = 224.2m USD
Long Term Debt = 300.0m USD (from longTermDebt, last quarter)
Short Term Debt = 13.8m USD (from shortTermDebt, last quarter)
Debt = 394.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 249.5m USD (from netDebt column, last quarter)
Enterprise Value = 10.87b USD (10.62b + Debt 394.5m - CCE 145.0m)
Interest Coverage Ratio = 10.01 (Ebit TTM 118.1m / Interest Expense TTM 11.8m)
EV/FCF = 48.51x (Enterprise Value 10.87b / FCF TTM 224.1m)
FCF Yield = 2.06% (FCF TTM 224.1m / Enterprise Value 10.87b)
FCF Margin = 18.41% (FCF TTM 224.1m / Revenue TTM 1.22b)
Net Margin = 6.41% (Net Income TTM 78.0m / Revenue TTM 1.22b)
Gross Margin = 65.54% ((Revenue TTM 1.22b - Cost of Revenue TTM 419.3m) / Revenue TTM)
Gross Margin QoQ = 66.37% (prev 62.72%)
Tobins Q-Ratio = 4.30 (Enterprise Value 10.87b / Total Assets 2.53b)
Interest Expense / Debt = 1.39% (Interest Expense 5.47m / Debt 394.5m)
Taxrate = 20.43% (9.81m / 48.0m)
NOPAT = 94.0m (EBIT 118.1m * (1 - 20.43%))
Current Ratio = 4.22 (Total Current Assets 609.5m / Total Current Liabilities 144.5m)
Debt / Equity = 0.20 (Debt 394.5m / totalStockholderEquity, last quarter 1.97b)
Debt / EBITDA = 1.11 (Net Debt 249.5m / EBITDA 224.2m)
Debt / FCF = 1.11 (Net Debt 249.5m / FCF TTM 224.1m)
Total Stockholder Equity = 2.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.96% (Net Income 78.0m / Total Assets 2.53b)
RoE = 3.91% (Net Income TTM 78.0m / Total Stockholder Equity 2.00b)
RoCE = 5.14% (EBIT 118.1m / Capital Employed (Equity 2.00b + L.T.Debt 300.0m))
RoIC = 4.06% (NOPAT 94.0m / Invested Capital 2.31b)
WACC = 9.96% (E(10.62b)/V(11.01b) * Re(10.29%) + D(394.5m)/V(11.01b) * Rd(1.39%) * (1-Tc(0.20)))
Discount Rate = 10.29% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.16%
[DCF Debug] Terminal Value 69.77% ; FCFF base≈232.4m ; Y1≈214.8m ; Y5≈194.2m
Fair Price DCF = 14.60 (EV 2.52b - Net Debt 249.5m = Equity 2.27b / Shares 155.8m; r=9.96% [WACC]; 5y FCF grow -9.56% → 2.90% )
EPS Correlation: -46.32 | EPS CAGR: -48.87% | SUE: -4.0 | # QB: 0
Revenue Correlation: 59.71 | Revenue CAGR: 1.67% | SUE: -0.59 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.56 | Chg30d=-0.001 | Revisions Net=-2 | Analysts=11
EPS current Year (2026-06-30): EPS=1.97 | Chg30d=-0.007 | Revisions Net=-4 | Growth EPS=+2.6% | Growth Revenue=+0.2%
EPS next Year (2027-06-30): EPS=2.17 | Chg30d=-0.022 | Revisions Net=-4 | Growth EPS=+10.0% | Growth Revenue=+6.6%
P/E Forward = 34.2466
P/S = 8.7285
P/B = 5.4024
P/EG = 0.8316
Revenue TTM = 1.22b USD
EBIT TTM = 118.1m USD
EBITDA TTM = 224.2m USD
Long Term Debt = 300.0m USD (from longTermDebt, last quarter)
Short Term Debt = 13.8m USD (from shortTermDebt, last quarter)
Debt = 394.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 249.5m USD (from netDebt column, last quarter)
Enterprise Value = 10.87b USD (10.62b + Debt 394.5m - CCE 145.0m)
Interest Coverage Ratio = 10.01 (Ebit TTM 118.1m / Interest Expense TTM 11.8m)
EV/FCF = 48.51x (Enterprise Value 10.87b / FCF TTM 224.1m)
FCF Yield = 2.06% (FCF TTM 224.1m / Enterprise Value 10.87b)
FCF Margin = 18.41% (FCF TTM 224.1m / Revenue TTM 1.22b)
Net Margin = 6.41% (Net Income TTM 78.0m / Revenue TTM 1.22b)
Gross Margin = 65.54% ((Revenue TTM 1.22b - Cost of Revenue TTM 419.3m) / Revenue TTM)
Gross Margin QoQ = 66.37% (prev 62.72%)
Tobins Q-Ratio = 4.30 (Enterprise Value 10.87b / Total Assets 2.53b)
Interest Expense / Debt = 1.39% (Interest Expense 5.47m / Debt 394.5m)
Taxrate = 20.43% (9.81m / 48.0m)
NOPAT = 94.0m (EBIT 118.1m * (1 - 20.43%))
Current Ratio = 4.22 (Total Current Assets 609.5m / Total Current Liabilities 144.5m)
Debt / Equity = 0.20 (Debt 394.5m / totalStockholderEquity, last quarter 1.97b)
Debt / EBITDA = 1.11 (Net Debt 249.5m / EBITDA 224.2m)
Debt / FCF = 1.11 (Net Debt 249.5m / FCF TTM 224.1m)
Total Stockholder Equity = 2.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.96% (Net Income 78.0m / Total Assets 2.53b)
RoE = 3.91% (Net Income TTM 78.0m / Total Stockholder Equity 2.00b)
RoCE = 5.14% (EBIT 118.1m / Capital Employed (Equity 2.00b + L.T.Debt 300.0m))
RoIC = 4.06% (NOPAT 94.0m / Invested Capital 2.31b)
WACC = 9.96% (E(10.62b)/V(11.01b) * Re(10.29%) + D(394.5m)/V(11.01b) * Rd(1.39%) * (1-Tc(0.20)))
Discount Rate = 10.29% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.16%
[DCF Debug] Terminal Value 69.77% ; FCFF base≈232.4m ; Y1≈214.8m ; Y5≈194.2m
Fair Price DCF = 14.60 (EV 2.52b - Net Debt 249.5m = Equity 2.27b / Shares 155.8m; r=9.96% [WACC]; 5y FCF grow -9.56% → 2.90% )
EPS Correlation: -46.32 | EPS CAGR: -48.87% | SUE: -4.0 | # QB: 0
Revenue Correlation: 59.71 | Revenue CAGR: 1.67% | SUE: -0.59 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.56 | Chg30d=-0.001 | Revisions Net=-2 | Analysts=11
EPS current Year (2026-06-30): EPS=1.97 | Chg30d=-0.007 | Revisions Net=-4 | Growth EPS=+2.6% | Growth Revenue=+0.2%
EPS next Year (2027-06-30): EPS=2.17 | Chg30d=-0.022 | Revisions Net=-4 | Growth EPS=+10.0% | Growth Revenue=+6.6%
Additional Sources for TECH Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle